Replies to post #803906 on NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

Do you recall people on this board were laughing over two years ago when I first mentioned about those vaccine manufacturing facilities at Merck West Point campus? Do you think they are still laughing now?

BTW, I keep smelling the incoming of generational wealth. For what the longs have been going through over the past many years, the longs fully deserve being rewarded with the generational wealth. IMO, we, the longs, are making contribution to humanity by making real cancer cure available to cancer patients first time in human history. How could we not be rewarded with the generational wealth? This is something I am gong to brag to my grandchildren.

Please read the following and let me know if it makes sense.

No one can ruin my investment with BS.

https://leanconstruction.org/blog/2024-lci-design-engineering-award-announcement/

The 63A project was initiated in December 2020 to provide a facility to house a multi-product syringe filling line that will deliver the safe, compliant, and reliable annual production of 70 million pre-filled syringes. The project will increase doses of vaccines by adding drug product capacity at the Merck PA manufacturing site. The vaccine produced helps protect individuals against diseases and related cancers. To achieve this goal, the project heavily utilized Lean tools, and developed a model termed ‘EPCM Integrator’ that would ensure meeting the project’s schedule and cost target.

Here are the DC vaccine trials which had pneumococcal vaccine in the combinations. Is it obvious that 'I' in Dr. Bosch's NYAS presentation stands for V116 (PCV21, CAPVAXIVE) manufactured and packaged at two manufacturing facilities B63 & B63A at Merck West Point Campus?

A Phase I Clinical Trial of Autologous Dendritic Cell Vaccine for Recurrent Ovarian or Primary Peritoneal Cancer
https://clinicaltrials.gov/study/NCT00683241
•Prevnar + DCVax-L + Bevacizumab (VEGF inhibitor) + Cyclophosphamide

Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma
https://clinicaltrials.gov/study/NCT03035331
•Intratumoral DCs + cryosurgery + pembrolizumab + Prevnar13

Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma
https://clinicaltrials.gov/study/NCT01239875
•Arm-A: Intratumoral DCs + cryosurgery + Pneumovax 23
•Arm-B: Intradermal DCs + Pneumovax 23

Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma
https://clinicaltrials.gov/study/NCT03325101
•Intratumoral DCs + Cryosurgery + pembrolizumab + Prevnar13

Dendritic Cell Vaccine for High Risk Ovarian Cancer Patients (DC-Ova)
https://clinicaltrials.gov/study/NCT00478452
•Arm-1: Trivalent killed influenza vaccine + Prevnar + DC-Ova
•Arm-2: Trivalent killed influenza vaccine + Prevnar + DC-Ova + Cyclophosphamide

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer
https://clinicaltrials.gov/study/NCT03942328

•Pilot Study: External Beam Radiation Therapy + DC vaccine + Prevnar 13
•Phase II Group 2: External Beam Radiation Therapy + DC vaccine + Prevnar 13 + Atezolizumab + Bevacizumab
•Phase II Group 3: External Beam Radiation Therapy + DC vaccine + Prevnar 13 + Atezolizumab + Tiragolumab